<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138290</url>
  </required_header>
  <id_info>
    <org_study_id>CL-01-IBR-02</org_study_id>
    <nct_id>NCT04138290</nct_id>
  </id_info>
  <brief_title>Post Marketing Study for the Evaluation of Predictix Antidepressant Clinician Software Support Tool in Prescribing Antidepressant Medication/s for the Treatment of Patients Suffering From Major Depressive Disorder</brief_title>
  <official_title>A Prospective Post Marketing Surveillance Study Study for the Evaluation of the Safety and Efficacy of the Predictix Antidepressant (PAD) Clinician Software Support Tool in Prescribing Antidepressant Medication/s for the Treatment of Patients Suffering From Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taliaz Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taliaz Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as an open label, one arm study. Up to 30 eligible patients will be
      enrolled, for whom the Predictix Antidepressant Software tool will be used when prescribed
      with a medication for their Major Depressive Disorder, by their treating physician.

      Visits will include the completion of several questionnaires designed to answer the study
      objectives, either as self-reported by the subjects and/ or by the clinician.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll up to 30 eligible patients, for whom the Predictix Antidepressant
      Software tool will be used when prescribed with a medication for their Major Depressive
      Disorder, by their treating physician.

      A treatment cycle will include four to five visits: Information consent and oral sampling,
      Baseline, 4 and 8 weeks. At least one completed cycle per patient is required for a patient
      to be included in the analysis as study completed.

      The treating physician will review and approve each subject's eligibility prior to his/ her
      entrance to the study and will review the Predictix Antidepressant software tool report prior
      to treatment start.

      Visits will include the completion of the Taliaz Ltd. Physician Form and several
      questionnaires designed to answer the study objectives Usability and satisfaction
      questionnaire/s will be analyzed for Usefulness, Satisfaction, Ease of Use and Learnability
      of the system.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is designed as an open label, one arm study</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>success rate of the Predictix tool</measure>
    <time_frame>8 weeks</time_frame>
    <description>A success will be defined as a score of 3 and below in the total improvement: measured by the CGI last measured value compared to Baseline, as well as a &gt;50% improvement measured by the QIDS16, under a specific medication cycle regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Usability</measure>
    <time_frame>8 weeks</time_frame>
    <description>Usability n questionnaire will be analyzed</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To evaluate the effect of device use on patients' care outcomes in terms of economic burden and social impact</measure>
    <time_frame>8 weeks</time_frame>
    <description>by analyzing the completed Work Productivity and Activity Impairment (WPAI) questionnaire.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Predictix Antidepressant Software tool</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Predictix Antidepressant Software tool will be used when prescribed with a medication for their MDD, by their treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Predictix Antidepressant Software tool</intervention_name>
    <description>Predictix Antidepressant is a stand-alone software tool based on a patients' genetic panel, clinical, demographic and behavioral inputs, intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with Major Depressive Disorder.</description>
    <arm_group_label>Predictix Antidepressant Software tool</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female at the age of 18 - 75 years old

          -  Indication of MDD diagnosis per DSM V

          -  Rule out other causes of depressive symptoms other than MDD apart from General Anxiety
             Disorder as authentified by the MINI*) (by Sheehan and Lecrubier ).

             *Up to a maximum of 15 completed GAD pts

          -  Ability to read, understand and sign an informed consent document

        Exclusion Criteria:

          -  Patient is diagnosed with other major psychopathologies (i.e. schizophrenia, bipolar
             disorder, psychotic depression, geriatric depression)

          -  Patient requires antipsychotic medication or mood stabilizers

          -  Patient is at substantial suicidal risk as judged by the treating physician

          -  Patient has attempted suicide in the past year.

          -  Patient has any current unstable medical condition or surgical illness

          -  Patient has history of seizure or convulsions.

          -  Patient has history of drug abuse or alcoholism in the last 6 months

          -  Inadequate communication with the patient

          -  In the investigator's judgement, patient is not able to provide written informed
             consent

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dekel Taliaz, Dr.</last_name>
    <phone>+972-77- 3352506</phone>
    <email>dekel@taliazhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno Millet, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

